Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133315) titled 'Short-term Efficacy and Safety of Abrocitinib 200 mg Combined with Topical Therapy in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study' on Sept. 24.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: The Fifth Affiliated Hospital, Sun Yat-sen University
Condition:
Atopic dermatitis
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-24
Target Sample Size: Atopic Dermatitis Observation Group:60;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=332763
Published by...